areas were affected ( Figure 1) . Her various treatments include high-potency topical corticosteroids, antiviral oral drugs, methotrexate, carbon dioxide, and erbium laser. Owing to the severity of the disease and the persistent lesions despite topical treatment, we decided to start apremilast treatment after verbal consent was given by the patient in March 2017. A physical global assessment (PGA) scale was used to assess the efficacy of the treatment, with 0 indicating clear; 1, almost clear; 2, moderate improvement; 3, slight improvement; 4, no change; and 5, worsening of the disease. After 1 month, the PGA level was 2 and decreased to 1 at 6 months. Tolerance was good with no adverse effects reported.
One month later she had familial stress and experienced a flare of HHD with the PGA level increasing to 4. She decided to stop the treatment. Two weeks after the medication was discontinued, the lesions were worse compared with the baseline level (PGA 5). We tried to treat the disease with twicedaily, high-potency topical corticosteroids, but with minimal efficacy. Finally, apremilast was reintroduced and, 1 month later, the PGA level was 3. At the time of writing, she was still receiving treatment.
Case 2
A woman in her 60s, with HHD diagnosed when she was aged 29 years, experienced axillary, submammary, abdominal, inguinal, and neck and back lesions ( Figure 2) . Five other members of her family also have HHD, including her mother, grandfather, 2 brothers, and her son. Her only comorbidity is hypertension. Over the years, she has tried topical medications, such as corticosteroids and tacrolimus, and botulinum toxin injections and has been hospitalized several times for HHD. She also received treatment with fractional, then continuous-wave carbon dioxide and erbium laser, as well as antiviral and antibiotic drugs, showing transient improvement on each occasion. Her usual treatment was valaciclovir once daily, along with topical corticosteroids.
She started apremilast treatment in June 2017, completing a 6-day titration period before taking 30 mg twice daily. The only adverse effect was diarrhea, with no more than 3 stools per day. After 1 month the PGA level was 3; the PGA level remained between 1 and 2 for the following 5 months of treatment.
Case 3
A woman in her 50s received a histologic diagnosis of HHD in 1999; her mother also has this disease. The patient also has hypothyroidism. The disease is localized in the patient's axillary, abdominal, neck, and back areas ( Figure 3) . She was treated successively with topical corticosteroids and tacrolimus, oral antivirals and antibiotics, injections of botulinum toxin, erbium laser, and methotrexate without success. She started apremilast after giving verbal consent in May 2017. The PGA level was 3 after 1 month, 2 after 3 months, and 1 after 6 months with no adverse effects reported. At the time of writing, she was still receiving apremilast and had almost stopped applying topical corticosteroids.
Key Points
Question Is apremilast, a phosphodiesterase-4 antagonist approved for the treatment of psoriasis, effective in the treatment of Hailey-Hailey disease?
Findings This case series presents 4 patients with treatment-resistant Hailey-Hailey disease whose symptoms showed improvement after 1 month with use of apremilast, 30 mg, twice daily.
Meaning In severe cases of Hailey-Hailey disease resistant to conventional treatments, apremilast appears to be a good, low-risk therapeutic alternative. 
Discussion
Hailey-Hailey disease has been treated with varying degrees of success using a variety of interventions aimed at reducing inflammation or triggering factors. The more severe forms of HHD are difficult to manage with only topical treatments or laser. Systemic approaches with cyclosporine, 2-5 methotrexate, 6,7 or thalidomide 8 have been proposed and gave isolated success.
There are increasing reports of data showing that keratinocytes are able to produce large amounts of chemokines, including CXCL10. 9, 10 We can hypothesize that the genetic alteration of keratinocytes in HHD can trigger their production of chemokines on stress or maceration and contribute to the clinical inflammation observed in this disease. Apremilast induces specific inhibition of phosphodiesterase-4, leading to T H 1 and T H 17 inhibition and a decrease of CXCL10 release. 11, 12 In the 4 patients described herein, apremilast showed a sustained improvement in symptoms during the 6 first months of treatment. The number and severity of lesions decreased and they were less inflammatory. As is always the case for HHD, recurrent flares occur. All of the patients experienced some recurrences during the follow-up period. During the first 6 months these recurrences were minimal and easily resolved with the use of topical corticosteroids. Two patients experienced a marked flare after 6 months of treatment and discontinued apremilast. The more severe flare developed after a familial stress event and did not respond to any treatment; however, the lesions improved significantly when apremilast was reintroduced.
Owing to the severity of their disease, 2 patients had a history of treatment with methotrexate, but this approach failed to improve their condition. Adverse effects were mild, including transient diarrhea and myalgia; however, 1 patient required a decrease of the dose for 1 month.
Limitations
The limitations of this study are the low number of patients treated and the absence of controls in a disorder classically presenting alternative periods of flares and spontaneous improvements. However, we included adults with severe, active, diffuse, and chronic erosions despite the daily use of topical treatment.
Conclusions
All of the patients experienced significant improvement of their condition with a marked reduction in the number and intensity of their flares for a follow-up period of 6 to 10 months. The response after reintroduction of apremilast for the patient who experienced a relapse after discontinuation of treatment also emphasizes the potential usefulness of apremilast in this indication. Taken together, these results suggest that apremilast could be a safe option to consider for treatment of severe and diffuse HHD. A prospective controlled trial is required to confirm these preliminary observations.
